Novavax (NASDAQ:NVAX) is trailing the leaders in the race to develop the first vaccine to protect against the novel coronavirus that causes COVID-19. But data from the first study of the vaccine, which goes by the code name NVX-CoV2373, suggests it was worth the wait.
In the phase 1 portion of the phase 1/2 clinical trial, two doses of NVX-CoV2373 induced neutralizing antibodies in every volunteer in the study. The company noted that the levels of antibodies "compared favorably to responses from patients with clinically significant COVID-19 disease."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,